Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction
Conditions: PD-1; Neoadjuvant Chemoradiotherapy; Gastroesophageal Junction Cancer Interventions: Drug: PD-1inhibitor Sponsors: Wuhan Union Hospital, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | China Health | COVID-19 | Gastroenterology | Hospitals | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research